artículo científico
Epstein-Barr Virus (EBV) Genome and Expression in Breast Cancer Tissue: Effect of EBV Infection of Breast Cancer Cells on Resistance (Taxol)
Fecha
2006-01Registro en:
1098-5514
10.1128/JVI.80.2.845-853.2006
Autor
Arbach, Hratch
Viglasky, Viktor
Lefeu, Florence
Guinebretière, Jean-Marc
Ramírez Mayorga, Vanessa
Bride, Nadège
Boualaga, Nadia
Bauchet, Thomas
Peyrat, Jean-Philippe
Mathieu, Marie-Christine
Mourah, Samia
Podgorniak, Marie-Pierre
Seignerin, Jean-Marie
Takada, Kenzo
Joab, Irène
Institución
Resumen
The Epstein-Barr virus (EBV) has been detected in subsets of breast cancers. In order to elaborate on these
observations, we quantified by real-time PCR (Q-PCR) the EBV genome in biopsy specimens of breast cancer
tissue as well as in tumor cells isolated by microdissection. Our findings show that EBV genomes can be
detected by Q-PCR in about half of tumor specimens, usually in low copy numbers. However, we also found that
the viral load is highly variable from tumor to tumor. Moreover, EBV genomes are heterogeneously distributed
in morphologically identical tumor cells, with some clusters of isolated tumor cells containing relatively high
genome numbers while other tumor cells isolated from the same specimen may be negative for EBV DNA. Using
reverse transcription-PCR, we detected EBV gene transcripts: EBNA-1 in almost all of the EBV-positive tumors
and RNA of the EBV oncoprotein LMP-1 in a smaller subset of the tissues analyzed. Moreover, BARF-1 RNA
was detected in half of the cases studied. Furthermore, we observed that in vitro EBV infection of breast
carcinoma cells confers resistance to paclitaxel (taxol) and provokes overexpression of a multidrug resistance
gene (MDRI). Consequently, even if a small number of breast cancer cells are EBV infected, the impact of EBV
infection on the efficiency of anticancer treatment might be of importance